Nektar Therapeutics

YTD

ALL

Trade Nektar Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.

CEO

Howard W. Robin

CEOHoward W. Robin

Employees

Employees63

Headquarters

San Francisco, California

HeadquartersSan Francisco, California

Founded

1990

Founded1990

Employees

Employees63

NKTR Key Statistics

Market cap

1.91B

Market cap1.91B

Price-Earnings ratio

-6.81

Price-Earnings ratio-6.81

Dividend yield

—

Dividend yield—

Average volume

1.06M

Average volume1.06M

High today

$57.69

High today$57.69

Low today

$55.36

Low today$55.36

Open price

$57.20

Open price$57.20

Volume

979.10K

Volume979.10K

52 Week high

$109.00

52 Week high$109.00

52 Week low

$7.99

52 Week low$7.99

Stock Snapshot

With a market cap of 1.91B, Nektar Therapeutics(NKTR) trades at $56.62. The stock has a price-to-earnings ratio of -6.81.

During the trading session on 2026-06-08, Nektar Therapeutics(NKTR) shares reached a daily high of $57.69 and a low of $55.36. At a current price of $56.62, the stock is +2.3% higher than the low and still -1.9% under the high.

Trading activity shows a volume of 979.1K, compared to an average daily volume of 1.06M.

Over the past 52 weeks, Nektar Therapeutics(NKTR) stock has traded between a high of $109.00 and a low of $7.99.

NKTR News

Simply Wall St 4h

Is Nektar Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program?

Nektar Therapeutics recently launched preparations for its Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis, alongside presenting at the Jef...

Simply Wall St 3d

A Look At Nektar Therapeutics Valuation After Recent Share Price Pullback - simplywall.st

...

TipRanks 3d

Nektar Stockholders Approve Governance and Incentive Plan Changes

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

90%

of 10 ratings

Buy

90%

Hold

10%

Sell

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.